button bars forest bayes pooled summary circles
benefit
(statisticaly significant) 		benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic (mCRPC) - 1st line (L1) castration-resistant prostate cancer (CRPC) metastatic (mCRPC) - 1st line (L1)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
abiraterone plus ADT vs. androgen deprivation therapy (ADT) 2 -37%--
apalutamide plus ADT vs. androgen deprivation therapy (ADT) 1 -33%--
docetaxel plus ADT vs. androgen deprivation therapy (ADT) 4 -24%--
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 -34%--
versus docetaxel plus ADT
abiraterone plus docetaxel plus ADT vs. docetaxel plus ADT 1 -25%--
darolutamide plus doxetaxel plus ADT vs. docetaxel plus ADT 1 -32%--

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons